# Sethera Therapeutics

**Type:** venture
**Status:** Draft
**Confidence:** Low
**Focus:** peptide therapeutics, enzymatic cross-linking, polymacrocyclic peptides, drug discovery platform
**Stage:** Early-stage; University of Utah spinout (~2023)
**Location:** Salt Lake City, UT
**Updated:** 2026-06-19
**Needs-reviewed:** 2026-06-19
**Hero:** https://picsum.photos/seed/sethera-therapeutics-2026/1600/1100
**Pull:** *Enzymatic peptide cross-linking to make unstable peptides drug-like — platform bet, very early.*
**Relates:** cites [Official Website: Sethera Therapeutics](sethera-therapeutics-official-website.md)

## Summary

Sethera Therapeutics is a Salt Lake City biotechnology company developing an enzymatic peptide cross-linking platform to synthesize stable polymacrocyclic peptides (pMCPs). Founded as a University of Utah spinout, the company offers partner-facing discovery capabilities — enzymatic library creation, hit identification, noncanonical building-block tuning, and modular recombination — compatible with phage, mRNA display, and DNA-encoded library screening.

The thesis: peptides can hit protein-protein interactions small molecules miss, but protease instability limits clinical use. Enzymatic site-specific thioether cross-linking could generalize stabilization across sequences — if the platform works beyond proof-of-concept. No clinical candidate or IND is publicly known.

## Impact

GLP-1 agonists demonstrated that stabilized peptides can become blockbuster medicines. If Sethera's enzymatic approach generalizes, it could open intracellular and PPI targets currently considered undruggable. Impact is entirely conditional on platform generalization — the first drug is the hard one; subsequent candidates would be faster if chemistry holds.

## What They Are Building

The pMCP Discovery Platform lets partners discover and engineer macrocyclic peptides with diverse architectures. The cyclization enzyme recognizes programmable sequence motifs to install thioether bonds, potentially multiple times per molecule. Sethera is actively seeking collaboration partners for target screening and drug-discovery programs.

## What They Need Now

Likely needs include peptide chemists, enzymologists, medicinal chemists, in-vivo pharmacologists, and platform-partnership business development. Very early team; broad roles and high individual leverage typical of academic spinouts.

## Who Could Help

Useful helpers include U of U technology-transfer connectors, peptide-platform pharma partners, GMP peptide-synthesis operators, and early biotech investors comfortable with 8–15 year platform timelines.

## Utah Context

Sethera is a U of U research spinout at 48 S Rio Grande Street in Salt Lake City, alongside Utah's peptide-and-biologics cluster ([Recursion Pharmaceuticals](recursion-pharmaceuticals.md), [3Helix](3helix.md), [CaLycia Biosciences](calycia-biosciences.md)).

## Evidence

- [Official Website: Sethera Therapeutics](sethera-therapeutics-official-website.md)

## Open Questions

- Does enzymatic stabilization generalize across peptide targets with preserved affinity, acceptable pharmacokinetics, and no new immunogenicity?
- Clinical-candidate timeline and lead-program disclosure — no IND or clinical program as of legacy intake.
- How does the platform compare with stapled peptides, macrocyclization companies, ADCs, and other peptide-stabilization approaches?
- Funding stage and team size beyond the official team page — legacy intake described stage-appropriate early funding only.
- Platform biotech plays typically need 8–15 years from founding to first approved drug; Sethera was founded ~2023.
- The placeholder hero should be replaced with a cleared platform or team image when rights are confirmed.